Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07460232 · ClinicalTrials.gov registry record · Early Phase 1
FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
A Early Phase 1 study, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT07460232: Recruiting Early Phase 1 study, sponsored by Mayo Clinic.
NCT07460232 is a Early Phase 1 study that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07460232, a Early Phase 1 study, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
Interventions
- DRUG Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2028-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07460232
The ClinicalTrials.gov registry entry for NCT07460232 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET is the first listed.
NCT07460232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07460232 about?
NCT07460232 is a clinical study titled "FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease". The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
What is the current status of trial NCT07460232?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2026-04-27. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07460232?
The interventions under investigation include: Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET (DRUG).
Who is sponsoring clinical trial NCT07460232?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.